Axiom Biotech develops automated microfluidic platforms that streamline cell therapy manufacturing, reducing production time from 14 days to 5 days. The Monash University spin-out holds IP on closed-loop cell sorting and expansion, and has attracted investment from major biotech VCs. Early customers include research hospitals across Australia and Asia-Pacific.